Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Jun 1, 2011
0
0